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Rosiglitazone decreases albuminuria in type 2
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Thiazolidinediones are insulin-sensitizing compounds that
reduce plasma glucose and improve the lipid profile of type 2
diabetic patients. We determined the effect of rosiglitazone
in 15 type 2 diabetic patients and compared these results to
14 randomly assigned placebo patients. After 3 months, the
urinary albumin to creatinine ratio was significantly
decreased, while the glucose metabolic clearance rate, during
insulin clamp, was significantly increased by rosiglitazone
compared to the placebo group. Fasting free fatty acid and
tumor necrosis factor-a (TNF-a) levels were significantly
decreased, while the adiponectin concentration was
significantly increased by rosiglitazone treatment. The
percentage decrease in albuminuria correlated with the
decrease in fasting plasma glucose, free fatty acids TNF-a
and the increase in fat mass, plasma adiponectin, and
glucose metabolic clearance rate. Stepwise linear regression
analysis showed the decrease in TNF-a and the increase in
adiponectin were independently associated with decreased
albuminuria. Our study indicates that thiazolidinediones may
be useful to prevent nephropathy in type 2 diabetic patients.
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Thiazolidinediones (TZDs) are insulin sensitizers that
decrease plasma glucose (PG) and improve lipid profile in
type 2 diabetes mellitus (T2DM) patients.1 TZDs initiate
their action by binding to peroxisome proliferator-activated
receptor-g (PPARg).1 Although PPARg receptors are most
abundant in fat cells,1,2 they have also been demonstrated in
kidney in mesangium and glomerulus.3,4 Studies in rodents
suggest that TZDs can prevent diabetic nephropathy,3,5,6 and
reduction in microalbuminuria has been demonstrated in
T2DM patients treated with TZDs in open-labeled trials.7,8
Inhibition of transforming growth factor-b1 and genes
involved in collagen/fibronectin formation and reduced
serum/renal interstitial tumor necrosis factor-a (TNF-a)
levels9,10 have been suggested as potential mechanisms for
renoprotective effect of TZDs,3 but the precise mechanism(s)
via which TZDs reduce albuminuria is yet to be defined.
Adiponectin, whose secretion is enhanced by TZDs, reduces
TNF-a levels, suppresses inflammatory actions of TNF-a,11
enhances endothelium-dependent/independent vasodilation,
stimulates nitric oxide (NO) production, and inhibits
endothelial cell proliferation.12,13 These vascular effects of
adiponectin could contribute to reduced albuminuria in
T2DM patients treated with TZDs. Elevated plasma free fatty
acid (FFA) levels14 and insulin resistance15,16 also have been
associated with microalbuminuria, the precursor of diabetic
nephropathy.
In this study, we examined the effect of rosiglitazone
(RSG) on urinary albumin excretion and related the decrease
to changes in insulin sensitivity and circulating adipocyto-
kines in T2DM patients. This represents the first placebo-
controlled study to examine the effect of TZDs on
microalbumin excretion and relate observed changes to
changes in insulin sensitivity and circulating adipocytokines,
which potentially could influence renal microalbumin
excretion.
RESULTS
Clinical characteristics and metabolic measurements
at baseline
The clinical characteristics and metabolic measurements at
baseline are summarized in Table 1. Placebo- and RSG-
treated groups were similar in age, gender, race, duration of
diabetes, blood pressure, body mass index, hemoglobin A1C
(HbA1C), fasting plasma glucose (FPG), insulin and lipids,
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fat mass (FM), and fat-free mass (FFM). The metformin-
treated group had higher (Po0.05) HbA1C and FPG
compared to placebo- and RSG-treated groups. There were
no significant differences in plasma FFA, leptin, adiponectin,
and TNF-a concentrations between RSG and placebo groups
before treatment. Serum creatinine concentration and
urinary albumin-to-creatinine ratio (UACR) were similar in
placebo, RSG, and metformin groups.
Effect of RSG on urinary albumin-to-creatinine ratio, 24-h
urinary albumin excretion, and 24-h creatinine clearance
A 12 weeks treatment of RSG reduced UACR by
8.771.7 mg/mg (Po0.01 vs baseline and vs placebo
(D¼ þ 4.372.9 mg/mg)). RSG significantly reduced 24-h
urinary albumin by 8.673.2 mg/day (Po0.05 vs baseline
and vs placebo (D¼ 3.476.5 mg/day)) without change in
24-h creatinine clearance (117712 to 114713 ml/min). In
the placebo group, neither the 24-h urinary albumin
excretion rate (23.276.8 to 26.779.5 mg/day) nor the 24-h
creatinine clearance (113714 to 100711 ml/min) changed
significantly from baseline. Metformin had no effect on
UACR (10.271.8 to 9.071.7 mg/mg, P40.50 vs RSG).
Serum creatinine and blood pressure did not change in
RSG or placebo groups (Table 2) or in the metformin group.
Effect of RSG on physiologic and metabolic parameters
After 12 weeks of RSG, there were significant increases in
body weight, body mass index, FM, high-density lipoprotein
cholesterol and significant decreases in HbA1C and FPG
(all Po0.001 vs baseline and vs placebo; Table 2). There were
no significant changes from baseline in any parameter in
the placebo group. During oral glucose tolerance test
Table 1 | Baseline clinical characteristics and metabolic parameters before RSG and placebo treatment
RSG Placebo Metformin
Age (years) 5472 (39–69)a 5672 (43–67)a 5272 (37–67)a
Gender (Male/female) 7/8 9/5 6/7
Body weight (kg) 8674 (67–118) 8775 (59–124) 8074 (51–94)
BMI (kg/m2) 3071 (24–37) 3071 (22–37) 3071 (21–36)
Systolic BP (mm Hg) 13372 (115–149) 13074 (93–153) 12573 (107–151)
Diastolic BP (mm Hg) 7872 (60–88) 7473 (51–91) 6972 (56–78)
Fat mass (kg) 3373 (17–59) 3373 (22–57) 3372 (18–42)
HbA1C (%) 8.770.4 (6.0–12.2) 8.370.4 (6.5–10.7) 10.470.5 (6.9–14.0)
FPG (mg/dl) 195711 (140–258) 18878 (150–235) 232712 (142–291)
Mean PG (OGTT; mg/dl) 293712 (196–357) 293711 (230–391) 326713 (224–392)
FPI (mU/ml) 1973 (9–46) 1673 (6–51) 1372 (2–23)
Mean PI (OGTT; mU/ml) 4278 (14–110) 3074 (8–69) 2173 (10–44)
Total chol (mg/dl) 18079 (128–242) 17275 (139–209) 17876 (150–212)
Triglycerides (mg/dl) 183715 (73–279) 155733 (68–537) 166717 (81–306)
HDL chol (mg/dl) 3473 (22–67) 3973 (28–62) 3372 (22–54)
LDL chol (mg/dl) 10878 (57–156) 10874 (88–134) 10276 (56–134)
Fasting FFA (mEq/l) 735752 (432–1060) 697741 (482–1009) 785767 (347–1067)
Mean FFA (OGTT; mEq/l) 561733 (380–834) 542743 (260–768) 631737 (379–910)
Adiponectin (mg/ml) 6.370.5 (4.1–11.7) 7.570.9 (2.9–15.4) NM
TNF-a (pg/ml) 5.870.4 (3.9–8.8) 4.770.2 (3.0–6.7) NM
Leptin (ng/ml) 14.472.8 (3.2–35.6) 8.971.3 (2.3–15.9) NM
Serum creatinine (mg/dl) 0.870.1 (0.5–1.1) 0.970.1 (0.5–1.5) 0.970.1 (0.5–1.2)
UACR (mg/mg Cr) 16.272.8 (4.4–43.7) 19.975.4 (0.0–66.1) 10.271.8 (4–25)
24 h UAE (mg/day) 18.573.5 (1.3–58) 23.276.8 (0–90)
24 h Cr clear (ml/min) 117712 (40–205) 113714 (37–240)
BMI, body mass index; BP, blood pressure; Chol, cholesterol; Cr clear, creatinine clearance; FFA, free fatty acids; FPG, fasting plasma glucose; FPI, fasting plasma insulin;
HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NM, not measured; OGTT, oral glucose tolerance test; PG, plasma glucose; PI, plasma
insulin; RSG, rosiglitazone; TNF-a, tumor necrosis factor-a; UACR, urinary albumin-to-creatinine ratio; UAE, urinary albumin excretion.
aNumbers in parentheses indicate range.
Table 2 | Effect of rosiglitazone onbody weight, fat mass,
parameters of glycemic control, plasma lipids, adipocytokine
levels, and urinary albumin/creatinine ratioa
Rosiglitazone Placebo P-value
DBody weight (kg) 3.770.8 070.4 o0.001
DBMI (kg/fm2) 1.370.3 070.1 o0.001
DFat mass (kg) 3.170.6 0.170.3 o0.001
DMean BP 3.472.2 1.571.2
DHbAlc (%) 1.370.3 0.570.3 o0.001
DFPG (mg/dl) 4578 0711 o0.01
DMean PG (OGTT) (mg/dl) 5779 4713 o0.01
DFPI (mU/ml) 472 173
DMean PI (OGTT) (mU/ml) 173 173
DTotal Chol (mg/dl) 1578 376
DTriglycerides (mg/dl) 2714 47732
DHDL (mg/dl) 472 372 o0.05
DLDL (mg/dl) 877 177
DFFA (mEq/l) 156735 81762 o0.05
DMean FFA (OGTT) (mEq/l) 137730 89747 o0.001
DAdiponectin (mg/ml) 9.971.2 0.270.4 o0.001
DTNF-a (pg/ml) 0.870.2 070.2 o0.05
DLeptin (ng/ml) 2.570.7 2.071.2
DSeram creatinine 0.0370.03 070.04
DUACR (fag/mg Cr) 8.771.7 4.372.9 o0.01
aSee legend in Table 1.
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(OGTT), mean PG (283712 to 23679 mg/dl) and FFA
(561733 to 424735 mEq/l) decreased (Po0.001 vs baseline
and vs placebo) without change in plasma insulin following
RSG (Table 2).
In the metformin-treated group, decreases in HbA1C
(10.470.5 to 7.770.4%), FPG (232712 to 150711 mg/dl),
and mean PG during OGTT (326713 to 22471 mg/dl; all
Po0.001 vs baseline) were significantly greater
(Po0.05–0.01) than in RSG-treated group.
Effect of RSG on circulating adipocytokines
Following RSG fasting plasma FFA (Po0.01 vs baseline and
vs placebo) and TNF-a (Po0.05 vs baseline and vs placebo)
concentrations decreased, while fasting plasma adipo-
nectin increased (Po0.001 vs baseline and vs placebo;
Table 2). Fasting plasma leptin increased (Po0.01) following
RSG, but the change was not significantly different
from placebo group. Metformin had no effect on fasting
plasma FFA.
Euglycemic insulin clamp
Before treatment, steady-state (90–120 min time period) PG
(9171 vs 8971 mg/dl) and insulin (7376 and 6574mU/ml)
concentrations were similar in RSG and placebo groups. After
12 weeks of RSG and placebo, PG and insulin concentrations
were similar to those during pretreatment insulin clamp.
Before treatment, basal endogenous glucose production
(EGP) was similar in RSG (3.2670.15 mg/kg FFM min) and
placebo (2.9970.09) groups. After 12 weeks, basal EGP
remained unchanged in placebo and decreased in RSG
(D¼0.4170.16 mg/kg FFM min, Po0.05 vs baseline and
placebo). During pretreatment insulin clamp, suppression of
EGP was similar in RSG and placebo groups (1.3770.15 vs
1.2070.13 mg/kg FFM min, respectively). After 12 weeks,
decrement in EGP during insulin clamp was slightly greater
in RSG (D¼0.3470.20 vs 0.1370.17 mg/kg FFM min,
P¼ 0.08 vs placebo). During pretreatment insulin clamp,
glucose MCR was similar in RSG and placebo groups
(2.7970.19 vs 3.7570.46 ml/kg FFM min, respectively).
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Figure 1 | Relationship between the percentage change (%D) in urinary albumin-to-creatinine ratio (UACR) vs the percentage
change in plasma FFA, serum TNF-a, and plasma adiponectin (ADP), and percentage change in insulin-stimulated glucose clearance
following treatment with placebo and rosiglitazone.
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Following 12 weeks of treatment, glucose MCR during
insulin clamp declined slightly (D¼0.2570.17 ml/kg
FFM min) in the placebo group and increased significantly
in the RSG group (D¼ 0.7570.17 ml/kg FFM min, Po0.01
vs baseline and Po0.001 vs placebo).
Following metformin treatment, basal EGP declined from
3.2670.13 to 2.7470.09 mg/kg FFM min (Po0.005), while
insulin-stimulated glucose MCR increased by 0.6170.27 ml/kg
FFM min (Po0.05 vs baseline and P¼NS vs RSG).
Regression analysis
When data before and after 12 weeks of RSG and placebo
were analyzed collectively, percentage change in UACR
correlated with percentage changes in FPG (r¼ 0.62,
Po0.01), FFA (r¼ 0.49, Po0.01), adiponectin (r¼0.69,
Po0.01), and TNF-a (r¼ 0.55, Po0.01) concentrations,
with percentage decline in HbA1C (r¼ 0.49, Po0.01), and
with insulin-stimulated glucose MCR (r¼0.48, Po0.01;
Figure 1). Percentage changes in FM, plasma leptin, mean
blood pressure, and creatinine clearance did not correlate
with percentage change in UACR. In backward stepwise
multiple regression analysis using the above parameters as
independent variables, only percentage changes in fasting
TNF-a (standard coefficient¼ 0.36, Po0.05) and adiponec-
tin (standard coefficient¼0.57, Po0.01) were significantly
and independently correlated with percentage change in
UACR (r2¼ 0.59, Po0.01). Similar correlations were ob-
served if the absolute values for the change in urinary
albumin excretion were related to the absolute change in the
parameters of interest.
With respect to metabolic parameters, change in fasting
plasma adiponectin was correlated with changes in EGP
(r¼0.41, Po0.05) and glucose MCR (r¼ 0.48, Po0.01)
during insulin clamp and with mean PG during OGTT
(r¼0.43, Po0.05). Change in mean plasma FFA concentra-
tion during OGTT was correlated with changes in EGP
(r¼ 0.43, Po0.05) and glucose MCR (r¼0.58, Po0.01)
during insulin clamp and with mean PG during OGTT
(r¼ 0.66, Po0.01). Increases in body weight and body fat
following treatment correlated with improvements in mean
PG during OGTT (r¼0.51, Po0.01), insulin-stimulated
glucose disposal during insulin clamp (r¼ 0.52, Po0.01), and
decline in fasting plasma FFA (r¼0.39, Po0.05) and mean
plasma FFA during OGTT (r¼0.40, Po0.05). Changes in
fasting TNF-a and leptin concentrations did not correlate with
changes in EGP or glucose MCR during insulin clamp.
DISCUSSION
In this double-blind, randomized, placebo-controlled study,
we examined the relationship between change in urinary
albumin excretion and improvement in insulin sensitivity
and circulating adipocytokine levels following RSG in T2DM
patients. Consistent with previous findings from our
laboratory and others,17,18 RSG enhanced both peripheral
(muscle) and hepatic insulin sensitivity, reduced HbA1C and
FPG, and improved glucose tolerance without any change in
plasma insulin concentration. Of particular note, 12 weeks of
RSG significantly decreased urinary albumin excretion (vs
both baseline and placebo) without any change in systolic or
diastolic blood pressure. The reduction in urinary albumin
excretion following RSG was associated with improved
metabolic control (FPG and insulin sensitivity) and
decreased circulating adipocytokine levels (TNF-a, adipo-
nectin, and FFA). However, in stepwise linear regression
analysis, only decreased TNF-a and increased adiponectin
concentrations were significantly and independently cor-
related with the decrease in UACR.
In rodents, TNF-a mRNA in glomeruli is increased,19,20
and elevated plasma TNF-a concentrations have been related
to development of diabetic nephropathy.9,14 Increased serum
and renal interstitial TNF-a levels also have been demons-
trated in diabetic nephropathy in rodents and humans.9,10
Diabetic nephropathy also has been associated with NO
deficiency.12,21 Since adiponectin enhances NO produc-
tion22,23 and since adiponectin levels are markedly reduced
in T2DM patients, this raises the possibility that adiponectin
deficiency may contribute to development of diabetic
nephropathy. Moreover, many studies,24,25 including the
present one, have demonstrated that TZDs increase plasma
adiponectin concentrations to supranormal levels. Since
adiponectin suppresses inflammatory actions of TNF-a11
and enhances endothelium-dependent/independent vasodila-
tion and NO production,11 this provides a potential
mechanism via which TZDs reduce urinary albumin excre-
tion. Many studies have demonstrated that transforming
growth factor-b in mesangial cells plays an important role in
pathogenesis of diabetic nephropathy.19 Cultured mesangial
cells express PPARg,4 and it has been suggested that PPARg
activation in mesangial cells by TZDs improves diabetic
nephropathy via inhibition of transforming growth factor-b,
independent of any glucose-lowering effect.5
The decrement in urinary albumin excretion following RSG
also correlated with improved peripheral (muscle) insulin
sensitivity. Although reduction in UACR also correlated with
decreases in FPG and HbA1C, in a stepwise linear regression
analysis, only changes in plasma adiponectin and TNF-a
independently correlated with decreased UACR. These ob-
servations, combined with our failure to observe any reduction
in UACR in T2DM patients treated with metformin to achieve
even greater reductions in HbA1C/FPG, argue against a role
for improved glycemic control as the mediator of decreased
urinary albumin excretion following RSG.
Previous studies have demonstrated a strong association
between microalbuminuria and insulin resistance.15,16,26 It
has been suggested that the compensatory hyperinsulinemic
response to insulin resistance causes renal vasodilation,
elevated glomerular hydrostatic pressure gradient, and
augmented glomerular filtration rate, resulting in increased
albumin excretion. However, we failed to observe any
relationship between fasting/post-glucose-load plasma insu-
lin concentrations and UACR either before or after RSG. Our
results suggest that the association between improved insulin
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sensitivity and decreased UACR most likely results from an
insulin-sensitizing effect of RSG on adipocytes,12 leading to
inhibition of TNF-a and FFA release and to increased
adiponectin secretion.
Several studies have demonstrated that TZDs reduce
blood pressure8,27 and Bakris et al.8 attributed the decrease in
UACR in RSG-treated diabetic patients to the fall in blood
pressure. However, all diabetic patients in this study were
normotensive prior to RSG, we did not observe any blood
pressure change following RSG, and no correlation was found
between change in UACR and either absolute or change in
blood pressure. A recent meta-analysis of randomized control
trials of RSG in T2DM patients28 found no significant
changes in systolic or diastolic blood pressure. Therefore, it
seems unlikely that reduced blood pressure can explain the
decrease in microalbumin excretion in this study.
T2DM individuals are characterized by day-long elevated
plasma FFA levels due to resistance of fat cell to antilipolytic
effect of insulin. Consistent with previous studies from our
laboratory,18,25 RSG reduced fasting FFA concentration and
mean FFA during OGTT by 20 and 24%, respectively, and the
reduction in plasma FFA concentration correlated with the
decreases in FPG, mean PG during OGTT, and impaired
hepatic and peripheral (muscle) insulin sensitivity. These
results suggest that the insulin-sensitizing action of TZDs is
mediated, at least in part, by their FFA-lowering effect, that is
reversal of lipotoxicity. The reduction in FFA also correlated
with the decrease in UACR, but this correlation was lost in
multiple regression analysis.
Following RSG, plasma adiponectin increased in every
diabetic subject by a mean of 2.6-fold, and the increment in
plasma adiponectin was strongly correlated with increments
in both hepatic and peripheral (muscle) insulin sensitivity.
We previously reported similar results in a completely sepa-
rate group of T2DM subjects.25 We demonstrated that RSG
enhanced IRS-1 tyrosine phosphorylation, association of
IRS-1 with phosphatidylinositol 30 kinase, and phosphati-
dylinositol 30 kinase activity in the muscle of T2DM
patients.18 The improvement in insulin signaling was closely
correlated with reduction in plasma FFA concentration. Since
the increase in plasma adiponectin in the present study was
strongly related with reduction in plasma FFA, one could
postulate that the primary effect of adiponectin is to inhibit
lipolysis in adipocytes and/or increase fatty acid oxidation in
muscle,29 leading to decreased intracellular fatty acid meta-
bolites (i.e., fatty acyl CoA, diacylglycerol, and ceramides) and
enhanced insulin signaling.30,31 Alternatively, adiponectin
may have a direct effect on the insulin-signaling cascade.32
In summary, 12 weeks of RSG treatment significantly
decreased urinary albumin excretion without change in blood
pressure. Reduction in UACR was correlated with (i)
decreased plasma FFA and TNF-a levels, (ii) increased
plasma adiponectin concentration, and (iii) enhanced
peripheral tissue (muscle) insulin sensitivity. Only decreased
TNF-a and increased adiponectin were related to reduced
urinary albumin excretion, using multivariate analysis. These
results suggest that RSG, either acting directly on renal
PPARg receptors or indirectly by altering adipocytokine
release from fat cells, causes a reduction in urinary albumin
excretion. TZDs may prove useful in preventing diabetic
nephropathy in T2DM patients.
MATERIALS AND METHODS
Twenty-nine type 2 diabetic patients were recruited from the
outpatient clinic of Texas Diabetes Institute. Patients previously
treated with insulin or TZDs were excluded. For subjects treated
with angiotensin-converting enzyme (ACE) inhibitors (n¼ 4) or
calcium channel blockers (n¼ 1), dose was kept constant through-
out the study. Clinical and laboratory characteristics of RSG and
placebo groups are shown in Table 1. A separate group of 13 T2DM
subjects (age¼ 5272 years, body mass index¼ 3071,
FPG¼ 232712 mg/dl, and HbA1C¼ 10.470.5%) received open-
labeled metformin and served as controls for improved glycemic
control. Patients were in good health without evidence of cardiac,
hepatic, renal, or other chronic diseases as determined by history,
physical examination, and routine blood chemistries. Body weight
was stable (71.5 kg) for X3 months before study. No subject
participated in heavy or formal exercise program. Subjects gave
signed voluntary, informed consent prior to participation. The
protocol was approved by IRB of UTHSCSA.
Study design
The study had double-blind, placebo-controlled, parallel design for
RSG vs placebo groups. Subjects who were taking metformin or
sulfonylurea had the medication discontinued 6 weeks before study.
All subjects participated in single-blind, 6-week, placebo run-in,
during which FPG was measured weekly. Only subjects with o5%
variability in PG during last 3 weeks of this run-in period were
randomized to RSG or placebo. Fasting plasma lipids and HbA1C
were measured every 2 weeks during run-in period. A 24-h urine
sample for measurement of urinary creatinine and albumin
concentrations was obtained after the 6-week run-in period. On
the day of the 24-h urine collection, blood pressure was measured
after 5 min in supine position (mean of three determinations) and
after 5 min in sitting position (mean of three determinations), using
an automated blood pressure recording system (Dynamap, Colin
Medical Instruments, San Antonio, TX, USA). During the
week before randomization, subjects received (i) 75 g OGTT,
(ii) measurement of lean body and FM with 3H2O, and (iii)
euglycemic insulin clamp with [3-3H]glucose to quantitate hepatic
and peripheral tissue insulin sensitivity. Studies were carried out in
post-absorptive state at 0800 hours after 10- to 12-h overnight fast.
Following completion of these studies, subjects were randomized to
receive 12 weeks of RSG, 8 mg/day, or placebo at breakfast. Subjects
returned to Clinical Research Center at 0800 hours every 2 weeks for
measurement of FPG and body weight. Fasting lipids and HbA1C
were measured monthly. During the last week of double-blind
period, OGTT, euglycemic insulin clamp, and 24-h urine sample for
urinary creatinine and albumin measurements were repeated.
Diabetic patients treated with open-labeled metformin parti-
cipated in a protocol similar to that described above.
24-h urine collection
At 0800 hours, subjects voided and discarded the urine sample. All
subsequent urine samples were collected and stored in a container
kept under refrigeration. On the following morning, subjects reported
to CRC at 0800 hours and a final urine sample was obtained.
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OGTT
PG, FFA, and insulin concentrations were measured at 30, 15,
and 0 min. At time 0, subjects ingested 75 g of glucose in orange-
flavored water, and PG, FFA, and insulin were measured at 15-min
intervals for 2 h. At time 0, 100 mCi 3H2O bolus was given
intravenously; plasma tritiated water radioactivity was measured at
90, 105, and 120 min for calculation of FFM and FM.33
Euglycemic insulin clamp
Insulin sensitivity was assessed with euglycemic insulin clamp.34
At 0800 hours (180 min), a prime (25 mCi FPG/100)-continuous
(0.25mCi/min) infusion of [3-3H]glucose was started via catheter
placed into antecubital vein and continued throughout the study.
A second catheter was inserted retrogradely into a vein on the
dorsum of hand, which was placed in a heated box (601C). Baseline
arterialized venous blood for determination of plasma [3-3H]glu-
cose radioactivity and plasma glucose/insulin concentrations was
drawn at 30, 20, 10, 5, and 0 min. At time 0, prime-
continuous (40 mU/min m2) infusion of regular insulin (Novolin,
Novo Nordisk, Princeton, NJ, USA) was started and continued for
120 min. Plasma glucose was allowed to drop to 90 mg/dl, and it was
maintained at this level by adjusting a 20% dextrose infusion.
Throughout insulin clamp, blood was drawn every 5 min for plasma
glucose determination. Plasma insulin concentration and [3-3H]glu-
cose specific activity were measured every 10–15 min.
Assays
Plasma glucose was measured using the glucose oxidase method
(Glucose Analyzer; Beckman Instruments, Fullerton, CA, USA) and
plasma insulin by radioimmunoassay (Diagnostic Products,
Los Angeles, CA, USA). HbA1C was measured by affinity chromato-
graphy (Biochemical Methodology, Drower 4350; Isolab, Akron,
OH, USA) and plasma FFA by enzymatic colorimetric quantification
(Wako Chemicals, Neuss, Germany). Plasma total cholesterol and
triglyceride were measured enzymatically (Boehringer-Mannheim,
Indianapolis, IN, USA) on a Hitachi 704 autoanalyzer. High-density
lipoprotein cholesterol was measured enzymatically on the
Hitachi 704 autoanalyzer after precipitation of chylomicrons and
very low-density lipoprotein and low-density lipoprotein cholesterol
by phosphotungstic acid. Low-density lipoprotein cholesterol
was calculated from Friedewald equation. Tritiated glucose
specific activity was determined in deproteinized plasma samples.
TNF-a concentration was determined with the sandwich ELISA
kit (detection limit¼ 0.5 pg/ml; intra- and inter-assay coefficients
of variation (CVs) of 5.7 and 7.5%; Quantikine; R&D Systems,
Minneapolis, MN, USA). Plasma leptin and adiponectin concen-
trations were determined by radioimmunoassay (Linco Research,
St Charles, MO, USA). Urinary creatinine concentration was
measured with the modified Jaffe method, and urinary albumin
concentration was determined by radioimmunoassay (Diagnostic
Products).
Calculations
Under post-absorptive conditions, rate of endogenous glucose
appearance (Ra) equals rate of glucose disappearance, and is
calculated as [3-3H]glucose infusion rate (d.p.m./min) divided by
steady-state plasma [3-3H]glucose specific activity (d.p.m./mg).
During insulin clamp, non-steady conditions prevail and Ra was
calculated from Steele’s equation. EGP was calculated as Ra minus
exogenous glucose infusion rate. Total glucose disposal equals sum
of residual EGP plus exogenous glucose infusion rate. Total body
glucose metabolic clearance rate (MCR) equals total glucose disposal
rate divided by plasma glucose concentration.
Total body water was determined from mean plasma 3H2O
radioactivity at time 90, 105, and 120 min after intravenous bolus of
3H2O. Plasma
3H2O specific activity was calculated assuming plasma
volume represents 93% of total volume. FFM was calculated by
dividing total body water by 0.73.35
Areas under the curve (AUCs) for glucose, insulin, and FFA
during OGTT were determined using the trapezoidal rule. Mean PG,
insulin, and FFA concentrations during OGTT were calculated by
dividing area under the curve by 120 min.
Statistical analysis
The statistical analysis was performed with StatView for Windows
(SAS Institute, Cary, NC, USA). Values before and after treatment
within each group were analyzed using paired Student’s t-test.
Comparison between groups was performed using analysis of
variance with Bonferroni/Dunn post hoc testing. Pearson’s correla-
tions between continuous variables were used as a measure of
association. Stepwise multiple linear regression analysis was
performed to examine multiple correlations among variables. Data
are presented as mean7s.e. P-value o0.05 was considered
statistically significant.
REFERENCES
1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.
2. Bays H, Mandarino L, DeFronzo RA. Role of the adipocytes FFA and
ectopic fat in the pathogenesis of type 2 diabetes mellitus. PPAR agonists
provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89:
463–478.
3. Guan Y, Breyer M. Peroxisome proliferator-activated receptors (PPARs).
Novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14–30.
4. Asano T, Wakisaka M, Yoshinari M et al. Peroxisome proliferator-activated
receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and
PPARgamma agonists modulate its differentiation. Biochim Biophys Acta
2000; 1497: 148–154.
5. Ishiki K, Haneda M, Koya D et al. Thiazolidinedione compounds
ameliorate glomerular dysfunction independent of their insulin-
sensitizing action in diabetic rats. Diabetes 2000; 49: 1022–1032.
6. McCarthy KJ, Routh RE, Shaw W et al. Troglitazone halts diabetic
glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;
58: 2341–2350.
7. Iwano E, Kanda T, Nakatani Y et al. Effect of troglitazone on
microalbuminuria in patients with incipient diabetic nephropathy.
Diabetes Care 1998; 21: 2135–2139.
8. Bakris G, Viberti G, Weston WM et al. Rosglitazone reduces urinary
albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7–12.
9. Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of
interleukin-18 and tumor necrosis factor-a in serum of patients with
type 2 diabetes mellitus: relationship with diabetic nephropathy.
Metabolism 2003; 52: 605–608.
10. Kalantarinia K, Awad AS, Siragy H. Urinary and renal interstitial
concentrations of TNF-a increase prior to albuminuria in diabetic rats.
Kidney Int 2003; 64: 1208–1213.
11. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes
and vascular function. J Clin Endocrinol Metab 2004; 89: 2563–2568.
12. Prabhakar S. Role of nitric oxide in diabetic nephropathy. Sem Nephrol
2004; 24: 333–344.
13. Stehouwer CDA, Henry RMA, Dekker JM et al. Microalbuminuria is
associated with impaired brachial artery, flow-mediated vasodilation in
elderly individuals without and with diabetes: further evidence for a link
between microalbuminuria and endothelial dysfunction. Kidney Int 2004;
66: S42–S44.
14. Yu Y, Suo L, Yu H et al. Insulin resistance and endothelial dysfunction in
type 2 diabetic patients with or without microalbuminuria. Diabetes Res
Clin Pract 2004; 65: 95–104.
15. Palaniappan L, Carnethon M, Fortmann SP. Association between
microalbuminuria and the metabolic syndrome: NHANES III. Am J
Hypertens 2003; 16: 952–958.
1372 Kidney International (2007) 72, 1367–1373
o r i g i n a l a r t i c l e Y Miyazaki et al.: Rosiglitazone and albumin excretion
16. Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension
and microalbuminuria in patients with type 2 (non-insulin-dependent)
diabetes mellitus. Diabetologia 1993; 36: 642–647.
17. Mayerson AB, Hundal S, Dufour S et al. The effects of rosiglitazone
on insulin sensitivity, lipolysis and hepatic and skeletal muscle
triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:
797–802.
18. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves
downstream insulin-receptor signaling in type 2 diabetic patients.
Diabetes 2003; 52: 1943–1950.
19. Nakamura T, Fukui M, Ebihara I et al. mRNA expression of growth factors
in glomeruli from diabetic rats. Diabetes 1993; 42: 450–456.
20. Hasegawa G, Nakano K, Sawada M et al. Possible role of tumor necrosis
factor and interleukin-1 in the development of diabetic nephropathy.
Kidney Int 1991; 40: 1007–1012.
21. Trachtman H, Futterweit S, Crimmins DL. High glucose inhibits nitric
oxide production in cultured rat mesangial cells. J Am Soc Nephrol 1997;
8: 1276–1282.
22. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates
nitric oxide production in vascular endothelial cells. Diabetologia 2003;
46: 1543–1549.
23. Chen H, Montagnani M, Shimomura I, Quon MJ. Adiponectin stimulates
nitric oxide production in vascular endothelial cells. J Biol Chem 2003;
278: 45021–45026.
24. Tiikkainen M, Hakkinen AM, Nyman T et al. Effects of rosiglitazone and
metformin on liver fat content, hepatic insulin resistance, insulin
clearance and gene expression in adipose tissue in patients with type 2
diabetes. Diabetes 2004; 53: 2169–2176.
25. Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on
circulating adipocytokine levels and insulin sensitivity in type 2 diabetic
patients. J Clin Endocrinol Metab 2004; 89: 4312–4319.
26. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is
associated with insulin resistance in nondiabetic subjects: the insulin
resistance atherosclerosis study. Diabetes 1998; 47: 793–800.
27. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while
glibenclamide worsens blood pressure control in treated hypertensive
diabetic and dyslipidemic subjects via modulation of insulin resistance
and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215–222.
28. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the
effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med
2004; 164: 2097–2104.
29. Civaterese AE, Ukropcova B, Carling S et al. Role for adiponectin in human
skeletal muscle bioenergetics. Cell Metab 2006; 4: 75–87.
30. Itani SI, Ruderman NB, Schneider F, Boden G. Lipid-induced insulin
resistance in human muscle is associated with changes in diacylglycerol,
protein kinase C and IkB-a. Diabetes 2002; 51: 2005–2011.
31. Ellis BA, Poynten A, Lowy AJ et al. Long-chain acyl-CoA esters as
indicators of lipid metabolism and insulin sensitivity in rat and human
muscle. Am J Physiol 2000; 279: E554–E560.
32. Satoh H, Nguyen MT, Trujillo M et al. Adenovirus-mediated adiponectin
expression augments skeletal muscle insulin sensitivity in male Wistar
rats. Diabetes 2005; 54: 1304–1313.
33. Bonora E, Del Prato S, Bonadonna RC et al. Total body fat content and
fat topography are associated differently with in vivo glucose metabolism
in nonobese and obese nondiabetic women. Diabetes 1992; 41:
1151–1159.
34. DeFronzo RA, Tobin JD, Anders R. Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Physiol 1979; 237:
E214–E223.
35. Hume R, Weyers E. Relationship between total body water and
surface area in normal and obese subjects. J Clin Pathol 1971; 24:
234–238.
Kidney International (2007) 72, 1367–1373 1373
Y Miyazaki et al.: Rosiglitazone and albumin excretion o r i g i n a l a r t i c l e
